Myocardial infarction and gastro-intestinal bleeding risks associated with aspirin use among elderly individuals with type 2 diabetes

Annals of Medicine

Volumn 46, Issue 5, 2014, Pages 335-340

  Sirois, Caroline ^a,b,c   Moisan, Jocelyne ^b,c   Poirier, Paul ^b,d   Grégoire, Jean Pierre ^b,c  

^a UNIVERSITÉ DU QUÉBEC À RIMOUSKI   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c University Laval   (Canada)

^d LAVAL UNIVERSITY   (Canada)

Author keywords

Aspirin; Diabetes mellitus; Hemorrhage; Myocardial infarction

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; CORTICOSTEROID; CYTOPROTECTIVE AGENT; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; PARACETAMOL; SULFONYLUREA; ANTIDIABETIC AGENT; ANTITHROMBOCYTIC AGENT;

AGED; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; CANADA; CASE CONTROL STUDY; CHEMICALLY INDUCED; COMPLICATION; DIABETES MELLITUS, TYPE 2; FACTUAL DATABASE; MYOCARDIAL INFARCTION; PRIMARY PREVENTION; RISK; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ASPIRIN; CASE-CONTROL STUDIES; COHORT STUDIES; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION; QUEBEC; RISK;

EID: 84905498307     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2014.902636     Document Type: Article

References (29)

1. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care. 2011;34:S11-61.
2. Pignone M, Alberts M, Colwell J, Cushman M, Inzucchi SE, Mukherjee D, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation. 2010;121:2694-701.
3. Sirois C, Poirier P, Moisan J, Grégoire J-P. The benefit of aspirin therapy in type 2 diabetes: what is the evidence? Int J Cardiol. 2008; 129: 172-9.
4. Nicolucci A, De Berardis G, Sacco M, Tognoni G. AHA/ADA vs. ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions. Eur Heart J. 2007;28:1925-7.
5. Pignone M, Williams C. Aspirin for primary prevention of cardiovascular disease in diabetes mellitus. Nat Rev Endocrinol. 2010; 6:619-28.
6. Zhang C, Sun A, Zhang P, Wu C, Zhang S, Fu M, et al. Aspirin for primary prevention of cardiovascular events in diabetes: a meta-analysis. Diabetes Res Clin Pract. 2010;87:211-18.
7. Butalia S, Leung AA, Ghali WA, Rabi DM. Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis. Cardiovasc Diabetol. 2011; 10: 25.
8. Stavakis S, Stoner J, Azar M, Wayangankar S, Th adani U. Low dose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. Am J Med Sci. 2011; 341: 1-9.
9. Millar WJ, Young TK. Tracking diabetes: prevalence, incidence and risk factors. Health Rep. 2003;14:35-47.
10. Ouhoummane N, Abdous B, Louchini R, Rochette L, Poirier P. Trends in postacute myocardial infarction management and mortality in patients with diabetes. A population-based study from 1995 to 2001. Can J Cardiol. 2010; 26: 523-31.
11. Patrono C, Rocca B. Aspirin: promise and resistance in the new millennium. Arterioscler Tromb Vasc Biol. 2008;28:s25-32.
12. Patrono C, Garcia Rodriguez LA, LandolfiR, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005; 353:2373-83.
13. Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Québec. J Clin Epidemiol. 1995; 48: 999-1009.
14. Levy AR, Tamblyn RM, Fitchett D, McLeod P, Hanley JA. Coding accuracy of hospital discharge data for elderly survivors of myocardial infarction. Can J Cardiol. 1999;15:1277-82.
15. Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J. 2004;148:99-104.
16. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol. 2001; 154: 854-64.
17. Belsley D, Kuh E, Welsch R. Regression diagnostics: identifying influential data and sources of collinearity. New York: Wiley; 1980.
18. Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009; 373: 1849-60
19. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321:129-35.
20. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A, PPP Collaborative Group. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care. 2003; 26: 3264-72.
21. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008; 337: a1840.
22. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008; 300: 2134-41.
23. Rocca B, Santilli F, Pitocco D, Mucci L, Petrucci G, Vitacolonna E, et al. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. J Thromb Haemost. 2012; 10: 1220-30.
24. Garcia Rodriguez LA, Hernandez-Diaz S, de Abajo FJ. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol. 2001; 52: 563-71.
25. De Berardis G, Lucisano G, D'Ettore A, Pellegrini F, Lepore V, Tognoni G, et al. Association of aspirin use with major bleeding in patients with and without diabetes. JAMA. 2012; 307; 2286-94.
26. Moride Y, Abenhaim L. Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol. 1994;47:731-7.
27. Rahme E, Barkun A, Nedjar H, Gaugris S, Watson D. Hospitalizations for upper and lower GI events associated with traditional NSAIDs and acetaminophen among the elderly in Quebec, Canada. Am J Gastroenterol. 2008; 103: 872-82.
28. Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ. 2006; 174: 169-74.
29. Guénette L, Sirois C. Pharmacy record registration of acetyl salicylic acid (ASA) prescriptions in Quebec. J Pharm Pharmaceut Sci. 2012; 15:252-5.